Remove 2001 Remove Clinical Trials Remove Treatment
article thumbnail

SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study

Cannabis Law Report

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. ” About The Study.

article thumbnail

UK Article: Why Don’t We Just… reschedule psilocybin?

Cannabis Law Report

Psychedelic medicine could provide much needed treatment options for some mental health and neurological disorders in the near future. There are a number of differences between PAP and current treatment approaches. This is because of the status of psychedelics as Schedule 1 drugs, under the Misuse of Drugs Regulations 2001.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK: Tory MP Crispin Blunt At Loggerheads With The Home Office Over Psilocybin Research

Cannabis Law Report

This change would mean it would be easier to run trials on its use in mental health treatments. The Prime Minister had already approved the rescheduling of psilocybin for exploring its potential as a treatment for depression, which he informed Mr Blunt in a meeting in May. Source: [link].

article thumbnail

Study: CBD “Promising” Therapy for Cocaine Addiction

CannaMD

Current Cocaine Treatments. As researchers point out: There is no gold standard pharmacological treatment for dependence on cocaine. Although several drugs have been investigated, there is no strong or consistent evidence indicating any of these drugs for the treatment of cocaine use disorder. mice/rats).

Therapy 98
article thumbnail

Why we haven’t cured cancer

Otherside Farms

Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. cancer cells (full – 2001). Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor1 (full – 2001). full – 2001).

article thumbnail

Medicinal Cannabis – How far have we really come?

Cannabis Law Report

Natalie has worked with private hospitals and clinics in relation to medical malpractice claims, and assisted on cases involving medical devices product liability and clinical trials. Acting on a broad range of cases, all with a medical or injury element, usually on the instructions of insurers. Legalisation. The Reality.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 25, November/December 2001.